LLYLoxo Oncology, Inc.Running, no new patients
A Study of Pirtobrutinib (LOXO-305) Versus Bendamustine Plus Rituximab (BR) in Untreated Patients With Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL)
Chronic Lymphocytic Leukemia · Small Lymphocytic Lymphoma
0Calmworry score, out of 100
No strong warning signs right now. The score counts warning signs; it is not a prediction.
Why this score
No warning signs right now. That's why the score is 0.
Score over time
- Stage
- Phase 3
- Patients
- 282 (final count)
- Started
- Sep 23, 2021
- Main results expected
- Jul 11, 2025
- Fully finished
- Oct 2027
- Results posted
- Sep 25, 2026
What counts as success
The trial's main goal(s), called the “primary outcome.”
Arm A Compared to Arm B: Progression-free Survival (PFS), Assessed by Independent Review Committee (IRC)
Measured over: From randomization until documented disease progression or death (up to 40 months)
Changes Tremor has spotted
No changes since Tremor started watching this trial.
Show details (technical version)
Score inputs
- none
Raw record changes
- none yet
Trial ID NCT05023980 · record last updated 2026-09-25 · checked 2026-11-09 15:36 UTC